Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Prevention Of Morbidity In Sickle cell disease pilot phase
ISRCTN ISRCTN29004071
ClinicalTrials.gov identifier
Public title Prevention Of Morbidity In Sickle cell disease pilot phase
Scientific title
Acronym POMS
Serial number at source 99-NR-31
Study hypothesis In sickle cell anaemia, nocturnal oxyhaemoglobin desaturation is associated with low processing speed index, and this morbidity can be reduced with overnight auto Continuous Positive Airways Pressure (CPAP) and/or oxygen supplementation.
Lay summary
Ethics approval St Marys Hospital Research Ethics Committee has approved the pilot phase of this study on the 25th September 2006 (ref: 06/Q0403/133).
Study design Randomised single blind trial
Countries of recruitment United Kingdom
Disease/condition/study domain Sickle cell anaemia
Participants - inclusion criteria 1. Age more than four years old
2. Informed consent with assent in accordance with UK ethical committee (Central Office for Research Ethics Committees [COREC]) system must be signed by the patient's parent or legally authorised guardian acknowledging written consent to join the study. When suitable, patients will be requested to give their assent to join the study
3. Haemoglobin SS (homozygous sickle cell anaemia) diagnosed by standard techniques. Participating institutions must submit documentation of the diagnostic haemoglobin analysis
Participants - exclusion criteria 1. Existing respiratory failure
2. Decompensated cardiac failure
3. History of severe epistaxis
4. Trans-sphenoidal surgery, or trauma that could have left a cranio-nasopharyngeal fistula
5. Perforated ear drum
6. Bullous lung disease
7. Bypassed upper airway
8. Pneumothorax
9. Pathologically low blood pressure
10. Cerebral Spinal Fluid (CSF) leaks, abnormalities of the cribriform plate, prior history of head trauma, and/or pneumocephalus
11. Patients on chronic regular blood transfusion
12. Patient who received treatment with anti-sickling drugs or hydroxyurea within three months
13. Patient with other neurological problems, such as neurofibromatosis, lead poisoning, or tuberous sclerosis
14. Pregnancy
15. Sinus or middle ear infection (temporary)
Anticipated start date 01/11/2006
Anticipated end date 31/10/2007
Status of trial Completed
Patient information material
Target number of participants 22
Interventions Overnight auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation if mean overnight oxyhaemoglobin saturation is not more than 94% after two weeks of autoCPAP versus no treatment.
Primary outcome measure(s) Change in processing speed index.
Secondary outcome measure(s) 1. Frequency of pain measured via SMS and pain diary
2. Adverse events e.g. headache, anorexia, weight loss, nausea, vomiting, reduction in steady state red or white cell count
3. Change in blood pressure
4. Number of omissions on Conners Continuous Performance Test
5. Change in Chervin sleep questionnaire
6. Change in Behaviour Rating Inventory of Executive Function (BRIEF)
7. Change in number of abnormalities (Adam's criteria) on Trans Cranial Doppler (TCD)
Sources of funding The Stroke Association (PROG 4) (UK)
Trial website http://www.stroke.org.uk/research/funded_research/research_projects_programme_grants/research_region/london/preventing.html
Publications 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19570752
Contact name Prof  Fenella  Kirkham
  Address Neuroscience Unit
Institute of Child Health
30 Guilford Street
  City/town London
  Zip/Postcode WC1N 1EH
  Country United Kingdom
Sponsor Institute of Child Health (UK)
  Address c/o Ms Emma Pendleton
Director of Research and Development
30 Guilford Street
  City/town London
  Zip/Postcode WC1N 1EH
  Country United Kingdom
  Sponsor website: http://www.ich.ucl.ac.uk/ich/
Date applied 19/11/2006
Last edited 28/04/2011
Date ISRCTN assigned 12/01/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central